POS0011 COMPARISON OF PSYCHOMETRIC PROPERTIES OF FOUR GLOBAL MEASURES OF PRESENTEEISM IN PATIENTS WITH OSTEOARTHRITIS AND INFLAMMATORY ARTHRITIS: A EULAR-PRO STUDY

Background Work is an important outcome for people with inflammatory arthritis (IA including PsA, RA, AxSpA) and osteoarthritis (OA). It known that IA OA are at increased risk of sick leave have to stop working early due ill health. In addition being becoming work disabled absenteeism, high levels presenteeism (i.e. reduced productivity/limited ability health whilst work) also been reported. Several instruments exist measure presenteeism, single-item global measures multi-item instruments. some studies using may be more feasible. However, available differ in concept, recall period reference. understand which the good psychometric properties before them clinical studies. Objectives To assess four Methods Patients or were recruited via rheumatology outpatient clinics a large international, longitudinal observational study 8 European countries Canada. Participants completed survey baseline, 1, 2, 3, 4 wks, 2 months 3 months. The included: Productivity Activity Impairment Questionnaire (WPAI), Scale–Rheumatoid Arthritis (WPS-RA), Ability Index (WAI) Quality*Quantity questionnaire (QQtotal/10) scale. facilitate score interpretation WAI QQtotal reversed. Pain was measured 11-point Likert Spearman correlations calculated between Workplace Limitations Scale (WALS), validated HAQ evaluate construct validity (validity: r <0.50=low; >0.50-<0.70=moderate; >0.70=high). Test-retest reliability scales (baseline-1wk) applying ICC patients stable disease same pain baseline 1wk) (reliability: ICC<0.40=poor; 0.40-0.75=fair good; >0.75=excellent). Responsiveness during comparing improvement (>1 point (~MCID pain)) no change worsening score. two groups compared Mann Whitney U test. Results This international included 550 mean age 47.8 (SD 9.9) yrs 61.4% female. Mean (SD) duration since diagnosis 10.8 (10.4) 91.2% had IA. scores were: WPAI=2.9 (2.7); WPS-RA=3.4 WAI=2.7 (2.4); QQtotal=3.1 (3.2). WALS moderate good, except low (Table 1). baseline-1wk (n=141) excellent, respectively: WPAI (0.771), WPS-RA (0.752), (0.663), (0.650). An month observed 145/381 (38%) patients. these significant reduction all those score: (-1.0 (2.37) vs 0.68 (2.40), p<0.01); (-0.76 (2.57) 0.43 (2.10), p<0.001); (-0.09 (2.34) 0.41 (2.46), (-0.57 (3.16) 0.79 (3.1), p<0.01). Table 1. - 0.8164 0.5992 0.5184 0.6269 0.5592 0.5836 0.5217 0.6055 0.5669 0.5866 0.5231 0.5168 0.5025 0.4367 Conclusion slightly better both measuring impact on productivity. Disclosure Interests Suzanne Verstappen Consultant of: EUOSHA, Grant/research support from: AbbVie, BMS. EULAR, Annelies Boonen Speakers bureau: Abbvie / Galapagos, Sarah Wilkinson: None declared, Dorcas Beaton: Ailsa Bosworth: José Canas da Silva: Gloria Crepaldi: Sabrina Dadoun: Cathie Hofstetter: Carina Mihai Boehringer-Ingelheim, Mepha, MED Talks Switzerland, Janssen, Roche, Sofia Ramiro Eli Lilly, MSD, Novartis, Pfizer, UCB, Sanofi, Grant: Garifallia Sakellariou Abbvie, BMS Galapagos., Sandra Meisalu: Johan K Wallman Amgen, Celgene, Pfizer., Diane Lacaille: declared